Why the study?
Heart failure and arrhythmia guideline recommendations did not include patients with muscular dystrophy, and the use of ivabradine had not previously been reported in limb girdle muscular dystrophy.
Does ivabradine improve symptoms and tolerability in a patient with limb girdle muscular dystrophy type 2I, cardiomyopathy, and inappropriate sinus tachycardia?
Case Report (n=1)
No
Does ivabradine improve symptoms and tolerability in a patient with limb girdle muscular dystrophy type 2I, cardiomyopathy, and inappropriate sinus tachycardia?
Ivabradine represents a novel, tolerable therapeutic option for managing inappropriate sinus tachycardia and cardiomyopathy in patients with limb girdle muscular dystrophy.
Answers are grounded in this paper and cite their sources.
May support ivabradine where beta-blockers cause side effects in muscular dystrophy; leaves open dedicated trials before practice change.
Muscular dystrophies are a heterogeneous group of disorders that commonly involve cardiac and skeletal muscle. Comprehensive guidelines for the management of cardiac failure and arrhythmias are available. However, the studies from which their recommendations are derived did not include any patients with muscular dystrophy. Some medications (eg, betablockers) may have significant side effects in this cohort. In some situations the use of agents with unique mechanisms of action such as ivabradine (a 'funny' channel inhibitor) may be more appropriate. Use of ivabradine has not previously been reported in limb girdle muscular dystrophy (LGMD). We describe the course of a patient with LGMD type 2I, cardiomyopathy and inappropriate sinus tachycardia treated with ivabradine. As advances in respiratory support have improved the outcomes of patients with muscular dystrophy; the prognostic significance of cardiac disease has increased. Ivabradine is tolerated and may reduce symptoms, morbidity and mortality in this cohort.
No takes yet. Share an insight, caveat, or question.
Rajendram et al. (2020) conducted a case report in Inappropriate sinus tachycardia and cardiomyopathy due to limb girdle muscular dystrophy type 2I (n=1). Ivabradine was evaluated on Heart rate control and symptom improvement.
Synapse has enriched 10 related papers. Consider them for comparative context: